Congratulations ... to YOU!

In the midst of the devastation in Haiti, MS patients have a reason to celebrate ...

... Fampridine SR (Dalfampridine / 4-Aminopyridine) is FDA approved as Ampyra.

Acorda's (ACOR) drug to be manufactured under licenses from Elan (ELN) will end the debate over who which drug will be the first oral medication for MS.

It is not Merck KGaA / EMD Serono's Cladribine (Mulinax/Movectro) or Novartis's (NVS) Fingolimod (FTY720), it is Acorda's neurofunctional enabler, Ampyra.

So, who are the stakeholders and how did they do?

Acorda ... won

Investors ... won

Patients ... won !!!!

Compounding pharmacies ... lost

My job now is to figure out the root of the word Ampyra (see my earlier blog on the sources for Amaya).

- Dr. Daniel Kantor, MD BSE
Medical Director
Neurologique

info@neurologique.org
www.neurologique.org